SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant oxaliplatin combination chemotherapy for colorectal cancer.
dc.contributor.author | Robles-Zurita, J | |
dc.contributor.author | Boyd, KA | |
dc.contributor.author | Briggs, AH | |
dc.contributor.author | Iveson, T | |
dc.contributor.author | Kerr, RS | |
dc.contributor.author | Saunders, Mark P | |
dc.contributor.author | Cassidy, J | |
dc.contributor.author | Hollander NH | |
dc.contributor.author | Tabernero, J | |
dc.contributor.author | Segelov, E | |
dc.contributor.author | Glimelius, B | |
dc.contributor.author | Harkin, A | |
dc.contributor.author | Allan, K | |
dc.contributor.author | McQueen, J | |
dc.contributor.author | Pearson, S | |
dc.contributor.author | Waterston, A | |
dc.contributor.author | Medley, L | |
dc.contributor.author | Wilson, C | |
dc.contributor.author | Ellis, R | |
dc.contributor.author | Essapen, S | |
dc.contributor.author | Dhadda, AS | |
dc.contributor.author | Hughes, R | |
dc.contributor.author | Falk, S | |
dc.contributor.author | Raouf, S | |
dc.contributor.author | Rees, C | |
dc.contributor.author | Olesen, RK | |
dc.contributor.author | Propper, D | |
dc.contributor.author | Bridgewater, J | |
dc.contributor.author | Azzabi, A | |
dc.contributor.author | Farrugia, D | |
dc.contributor.author | Webb, A | |
dc.contributor.author | Cunningham, D | |
dc.contributor.author | Hickish, T | |
dc.contributor.author | Weaver, A | |
dc.contributor.author | Gollins, S | |
dc.contributor.author | Wasan, HS | |
dc.contributor.author | Paul J | |
dc.date.accessioned | 2018-12-10T11:48:54Z | |
dc.date.available | 2018-12-10T11:48:54Z | |
dc.date.issued | 2018 | en |
dc.identifier.citation | Robles-Zurita J, Boyd KA, Briggs AH, Iveson T, Kerr RS, Saunders MP, et al. SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. Br J Cancer. 2018 Nov;119(11):1332-8. | en |
dc.identifier.pmid | 30420616 | en |
dc.identifier.doi | 10.1038/s41416-018-0319-z | en |
dc.identifier.uri | http://hdl.handle.net/10541/621407 | |
dc.description.abstract | BACKGROUND: The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3?M) versus the usually given 6 months (6?M) of adjuvant chemotherapy in colorectal cancer. METHODS: In total, 6088 patients with fully resected high-risk stage II or stage III colorectal cancer were randomised and followed up for 3-8 years. The within-trial cost-effectiveness analysis from a UK health-care perspective is presented using the resource use data, quality of life (EQ-5D-3L), time on treatment (ToT), disease-free survival after treatment (DFS) and overall survival (OS) data. Quality-adjusted partitioned survival analysis and Kaplan-Meier Sample Average Estimator estimated QALYs and costs. Probabilistic sensitivity and subgroup analysis was undertaken. RESULTS: The 3?M arm is less costly (-£4881; 95% CI: -£6269; -£3492) and entails (non-significant) QALY gains (0.08; 95% CI: -0.086; 0.230) due to a better significant quality of life. The net monetary benefit was significantly higher in 3?M under a wide range of monetary values of a QALY. The subgroup analysis found similar results for patients in the CAPOX regimen. However, for the FOLFOX regimen, 3?M had lower QALYs than 6?M (not statistically significant). CONCLUSIONS: Overall, 3?M dominates 6?M with no significant detrimental impact on QALYs. The results provide the economic case that a 3?M treatment strategy should be considered a new standard of care | en |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1038/s41416-018-0319-z | en |
dc.title | SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant oxaliplatin combination chemotherapy for colorectal cancer. | en |
dc.type | Article | en |
dc.contributor.department | Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK | en |
dc.identifier.journal | The British Journal of Cancer | en |
refterms.dateFOA | 2020-04-22T12:31:17Z |